{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002696","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.770808+00:00","generated_at":"2026-06-07T02:32:35.274885+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Monte Rosa outlines 2024 milestones: Fast Track for MRT-2359, MRT-6160 Phase 1, cash into H1 2026","bullets":["FDA Fast Track Designation for MRT-2359 in previously treated metastatic SCLC with L-MYC or N-MYC expression.","RP2D for MRT-2359 Phase 1/2 trial in MYC-driven solid tumors expected Q2 2024; new dose schedule initiated.","MRT-6160 (VAV1-directed MGD) IND submission H1 2024, Phase 1 SAD/MAD study in healthy volunteers mid-2024.","Cash runway into H1 2026; NEK7 development candidate nomination Q1 2024, CDK2 candidate in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002696","json":"https://secwatch.observer/filing/0000950170-24-002696.json","markdown":"https://secwatch.observer/filing/0000950170-24-002696.md","text":"https://secwatch.observer/filing/0000950170-24-002696.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024002696/0000950170-24-002696-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024002696/glue-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:32:35.274885+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}